Frequently Asked Questions
The market is segmented based on , By Type (Alcoholic and Non-Alcoholic), Treatment (Blood Test, Imaging Procedures, Liver Tissue Examination), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Fatty Liver Diseases Treatment Market size was valued at USD 9.15 USD Billion in 2022.
The Global Fatty Liver Diseases Treatment Market is projected to grow at a CAGR of 15% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer , AbbVie , Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., Novartis AG, Lupin, Cipla , Aurobindo Pharma, Takeda Pharmaceutical Company Limited, F. Hoffmann La Roche Ltd, Abbott, PT. Daewoong Pharmaceutical Company, Cardax .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
